elobixibat elobixibat elobixibat is an inhibitor of the ileal bile acid transporter (ibat), undergoing development in clinical trials for the treatment of chronic constipation and irritable bowel syndrome with constipation (ibs-c). elobixibatclinical dataroutes ofadministrationby mouthatc codea06ax09 (who) identifiers iupac name n-acetyl)amino]-2-phenylacetyl}glycine cas number439087-18-0pubchem cid9939892drugbankdb12486chemspider8115513unii865uek4ejckeggd10796chemblchembl3039515comptox dashboard (epa)dtxsid00195985 chemical and physical dataformulac36h45n3o7s2molar mass695.89 g·mol−13d model (jsmol)interactive image smiles o=c(o)cnc(=o)(c1ccccc1)nc(=o)coc4cc3c(n(c2ccccc2)cc(cs3(=o)=o)(cccc)cccc)cc4sc inchi inchi=inchi=1s/c36h45n3o7s2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34h,4-7,18-19,22-25h2,1-3h3,(h,37,43)(h,38,40)(h,41,42)/t34-/m1/s1key:xflqirakklnxrq-uuwrzzswsa-n mechanism of action elobixibat is an inhibitor of ibat, which is an alternative name for the apical sodium bile acid transporter (asbt) encoded by the slc10a2 gene. asbt/ibat is a bile acid:sodium symporter responsible for the reuptake of bile acids in the ileum, the initial step in their enterohepatic circulation. by inhibiting the uptake of bile acids, elobixibat increases the bile acid concentration in the gut, and this accelerates intestinal passage and softens the stool. following several phase ii studies, it is now undergoing phase iii trials. drug development the drug was developed by albireo ab, who licensed it to ferring pharmaceuticals for further development and marketing. albireo has partnered with ajinomoto pharmaceuticals, giving the japan-based company the rights to further develop the drug and market it throughout asia.